Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

This study has suspended participant recruitment.
(All dosing suspended temporarily)
Sponsor:
Information provided by (Responsible Party):
Akashi Therapeutics
ClinicalTrials.gov Identifier:
NCT01847573
First received: May 2, 2013
Last updated: February 3, 2016
Last verified: February 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)